<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855228</url>
  </required_header>
  <id_info>
    <org_study_id>C94-145</org_study_id>
    <secondary_id>C94-145</secondary_id>
    <nct_id>NCT03855228</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)</brief_title>
  <official_title>Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in the Treatment of Seasonal Allergic Rhinitis (Study No. C94-145)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of mometasone furoate nasal
      spray (MFNS) with the addition of loratadine vs MFNS alone, loratadine alone, or placebo, in
      the treatment of patients with seasonal allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 1995</start_date>
  <completion_date type="Actual">August 7, 1995</completion_date>
  <primary_completion_date type="Actual">August 7, 1995</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom Score (Assessed by Participant)</measure>
    <time_frame>Baseline and days 1 through 15 (average of 15 days of treatment)</time_frame>
    <description>Mean change from baseline (CFB), averaged over study days 1-15, is calculated for total nasal symptom scores assessed by participants. Participants scored 4 symptoms (rhinorrhea; nasal stuffiness; nasal itching; sneezing) in diaries on a scale from 0 (none) to 3 (severe). Scores sum to a total nasal symptom score (range: 0-12); higher values indicate greater severity. A decrease in symptom severity is reflected by a negative CFB.
CFB is the 15-day average score minus baseline score. Scores were recorded twice daily, in morning (AM) and night (PM). Average AM/PM scores are first calculated separately, then averaged together to compute the 15-day average score. If diary entries were missing, an average AM or PM score was not calculated. If neither average AM nor PM score was calculated, total 15-day average score was not calculated. Baseline score is an average of the three AM and three PM scores preceding treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Total Symptom Score (Assessed by Participant)</measure>
    <time_frame>Baseline and days 1 through 15 (average of 15 days of treatment)</time_frame>
    <description>Mean change from baseline (CFB), averaged over study days 1-15, is calculated for total symptom scores assessed by participants. Participants scored 8 symptoms (rhinorrhea; nasal stuffiness; nasal itching; sneezing; itching/burning eyes; tearing/watering eyes; eye redness; and ear/palate itching) in diaries on a scale from 0 (none) to 3 (severe). Scores sum to a total symptom score (range: 0-24); higher values indicate greater severity. A decrease in symptom severity is reflected by a negative CFB.
CFB is the 15-day average score minus baseline score. Scores were recorded twice daily, in morning (AM) and night (PM). Average AM/PM scores are first calculated separately, then averaged together to compute the 15-day average score. If diary entries were missing, an average AM or PM score was not calculated. If neither average AM nor PM score was calculated, total 15-day average score was not calculated. Baseline score is an average of the three AM and three PM scores preceding treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom Score on Day 15 (Assessed by Physician)</measure>
    <time_frame>Baseline and study day 15</time_frame>
    <description>The mean change from baseline on study day 15 was calculated for total nasal symptom scores assessed by physician. Total nasal symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, and sneezing scores. Physician scored each symptom during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-12 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Symptom Score on Day 15 (Assessed by Physician)</measure>
    <time_frame>Baseline and study day 15</time_frame>
    <description>The mean change from baseline on study day 15 was calculated for total symptom scores assessed by physician. Total symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, sneezing, itching/burning eyes, tearing/watering eyes, redness of the eyes, and itching of the ears or palate scores. Physician scored each symptom during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-24 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom Score on Day 8 (Assessed by Physician)</measure>
    <time_frame>Baseline and study day 8</time_frame>
    <description>The mean change from baseline on study day 15 was calculated for total nasal symptom scores assessed by physician. Total nasal symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, and sneezing scores. Physician scored each symptom during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-12 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Symptom Score on Day 8 (Assessed by Physician)</measure>
    <time_frame>Baseline and study day 8</time_frame>
    <description>The mean change from baseline on study day 8 was calculated for total symptom scores assessed by physician. Total symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, sneezing, itching/burning eyes, tearing/watering eyes, redness of the eyes, and itching of the ears or palate scores. Physician scored each symptom during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-24 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis (SAR) on Day 15 (Assessed by Physician)</measure>
    <time_frame>Baseline and study day 15</time_frame>
    <description>The mean change from baseline on study day 15 was calculated for overall condition of rhinitis. Physicians scored participant rhinitis condition during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe). A higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis (SAR) on Day 8 (Assessed by Physician)</measure>
    <time_frame>Baseline and study day 8</time_frame>
    <description>The mean change from baseline on study day 8 was calculated for overall condition of rhinitis. Physicians scored participant rhinitis condition during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe). A higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Therapy on Day 15 (Assessed by Physician)</measure>
    <time_frame>Study day 15</time_frame>
    <description>Mean response to therapy based on the participant's status relative to baseline. Physician scored participant's response on a scale from 1 (complete relief) to 5 (treatment failure) during study visit on study day 15. A higher value indicates weaker response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Therapy on Day 8 (Assessed by Physician)</measure>
    <time_frame>Study day 8</time_frame>
    <description>Mean response to therapy based on the participant's status relative to baseline. Physician scored participant's response on a scale from 1 (complete relief) to 5 (treatment failure) during study visit on study day 8. A higher value indicates weaker response.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">704</enrollment>
  <condition>Rhinitis, Allergic</condition>
  <arm_group>
    <arm_group_label>MFNS 200 µg + Loratadine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MFNS 200 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily administration of 200 µg of MFNS plus oral placebo tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loratadine 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate nasal spray (MFNS)</intervention_name>
    <description>Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.</description>
    <arm_group_label>MFNS 200 µg</arm_group_label>
    <arm_group_label>MFNS 200 µg + Loratadine 10 mg</arm_group_label>
    <other_name>SCH 32088</other_name>
    <other_name>MK-0887</other_name>
    <other_name>NASONEX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.</description>
    <arm_group_label>Loratadine 10 mg</arm_group_label>
    <arm_group_label>MFNS 200 µg + Loratadine 10 mg</arm_group_label>
    <other_name>Claritin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>Daily dose of placebo administered as a nasal spray for 15 days.</description>
    <arm_group_label>Loratadine 10 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Daily dose of placebo administered as an oral tablet for 15 days.</description>
    <arm_group_label>MFNS 200 µg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2-year history of seasonal allergic rhinitis

          -  Positive skin test response to a local seasonal allergen (current, or performed in
             investigator's office within the past year)

          -  Good health and free of any unstable, clinically significant disease, other than
             allergic rhinitis, that would interfere with the study schedule or evaluation of
             seasonal allergic rhinitis

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Women of childbearing potential who are not using an acceptable form of birth control

          -  Significant history of metabolic, cardiovascular, neurologic, hematologic, hepatic,
             gastrointestinal, cerebrovascular, respiratory, or renal disease, or any other
             disorder which, in the judgment of the investigator, could interfere with the study,
             or require treatment which might interfere with the study

          -  Use of any chronic medication which could affect the course of seasonal allergic
             rhinitis

          -  Asthma requiring chronic use of inhaled or systemic corticosteroids (inhaled
             bronchodilators are permitted for asthma treatment)

          -  Current or history of frequent, clinically significant sinusitis or chronic purulent
             postnasal drip

          -  Upper respiratory tract or sinus infection that requires antibiotic therapy within the
             previous 2 weeks, or a viral upper respiratory infection (URI) within the 7 days prior
             to Screening

          -  Dependence upon nasal, oral or ocular decongestants, or nasal topical antihistamines,
             in the opinion of the investigator

          -  Has rhinitis medicamentosa

          -  Evidence of clinically significant nasal candidiasis

          -  Investigational drug use within the previous 30 days

          -  Nasal structural abnormalities, including large nasal polyps and marked septal
             deviation, that significantly interfere with nasal air flow

          -  Immunotherapy (desensitization therapy), unless on a stable maintenance schedule for
             at least one month prior to the Screening visit

          -  History of multiple drug allergies, allergy to antihistamines or corticoids

          -  History of psychosis, antagonistic personality, poor motivation, hypochondriasis, or
             any other emotional or intellectual problems that are likely to limit the validity of
             consent to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <results_first_submitted>May 29, 2019</results_first_submitted>
  <results_first_submitted_qc>May 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2019</results_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MFNS 200 μg + Loratadine 10 mg</title>
          <description>Daily administration of 200 μg of Mometasone Furoate Nasal Spray (MFNS) plus oral dose of 10 mg loratadine tablet.</description>
        </group>
        <group group_id="P2">
          <title>MFNS 200 μg</title>
          <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
        </group>
        <group group_id="P3">
          <title>Loratadine 10 mg</title>
          <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="182"/>
                <participants group_id="P4" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="181">1 participant immediately dropped out prior to starting study intervention.</participants>
                <participants group_id="P4" count="176">1 participant immediately dropped out prior to starting study intervention.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="174"/>
                <participants group_id="P4" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Entry Requirements</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all randomized participants who received ≥1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>MFNS 200 μg + Loratadine 10 mg</title>
          <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
        </group>
        <group group_id="B2">
          <title>MFNS 200 μg</title>
          <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
        </group>
        <group group_id="B3">
          <title>Loratadine 10 mg</title>
          <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="169"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="181"/>
            <count group_id="B4" value="176"/>
            <count group_id="B5" value="702"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" spread="13.1"/>
                    <measurement group_id="B2" value="25.6" spread="13.2"/>
                    <measurement group_id="B3" value="25.2" spread="12.6"/>
                    <measurement group_id="B4" value="25.6" spread="13.3"/>
                    <measurement group_id="B5" value="25.5" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="350"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="169"/>
                    <measurement group_id="B5" value="672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="154"/>
                    <measurement group_id="B5" value="622"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Nasal Symptom Score (Assessed by Participant)</title>
        <description>Mean change from baseline (CFB), averaged over study days 1-15, is calculated for total nasal symptom scores assessed by participants. Participants scored 4 symptoms (rhinorrhea; nasal stuffiness; nasal itching; sneezing) in diaries on a scale from 0 (none) to 3 (severe). Scores sum to a total nasal symptom score (range: 0-12); higher values indicate greater severity. A decrease in symptom severity is reflected by a negative CFB.
CFB is the 15-day average score minus baseline score. Scores were recorded twice daily, in morning (AM) and night (PM). Average AM/PM scores are first calculated separately, then averaged together to compute the 15-day average score. If diary entries were missing, an average AM or PM score was not calculated. If neither average AM nor PM score was calculated, total 15-day average score was not calculated. Baseline score is an average of the three AM and three PM scores preceding treatment.</description>
        <time_frame>Baseline and days 1 through 15 (average of 15 days of treatment)</time_frame>
        <population>Includes randomized participants with ≥1 valid post-Baseline visit, no major protocol violations, and evaluable data for the days 1-15 average.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Nasal Symptom Score (Assessed by Participant)</title>
          <description>Mean change from baseline (CFB), averaged over study days 1-15, is calculated for total nasal symptom scores assessed by participants. Participants scored 4 symptoms (rhinorrhea; nasal stuffiness; nasal itching; sneezing) in diaries on a scale from 0 (none) to 3 (severe). Scores sum to a total nasal symptom score (range: 0-12); higher values indicate greater severity. A decrease in symptom severity is reflected by a negative CFB.
CFB is the 15-day average score minus baseline score. Scores were recorded twice daily, in morning (AM) and night (PM). Average AM/PM scores are first calculated separately, then averaged together to compute the 15-day average score. If diary entries were missing, an average AM or PM score was not calculated. If neither average AM nor PM score was calculated, total 15-day average score was not calculated. Baseline score is an average of the three AM and three PM scores preceding treatment.</description>
          <population>Includes randomized participants with ≥1 valid post-Baseline visit, no major protocol violations, and evaluable data for the days 1-15 average.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="2.2"/>
                    <measurement group_id="O2" value="7.8" spread="2.2"/>
                    <measurement group_id="O3" value="7.9" spread="2.2"/>
                    <measurement group_id="O4" value="8.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline Days 1-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="2.6"/>
                    <measurement group_id="O2" value="-2.7" spread="2.5"/>
                    <measurement group_id="O3" value="-1.9" spread="2.2"/>
                    <measurement group_id="O4" value="-1.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Symptom Score (Assessed by Participant)</title>
        <description>Mean change from baseline (CFB), averaged over study days 1-15, is calculated for total symptom scores assessed by participants. Participants scored 8 symptoms (rhinorrhea; nasal stuffiness; nasal itching; sneezing; itching/burning eyes; tearing/watering eyes; eye redness; and ear/palate itching) in diaries on a scale from 0 (none) to 3 (severe). Scores sum to a total symptom score (range: 0-24); higher values indicate greater severity. A decrease in symptom severity is reflected by a negative CFB.
CFB is the 15-day average score minus baseline score. Scores were recorded twice daily, in morning (AM) and night (PM). Average AM/PM scores are first calculated separately, then averaged together to compute the 15-day average score. If diary entries were missing, an average AM or PM score was not calculated. If neither average AM nor PM score was calculated, total 15-day average score was not calculated. Baseline score is an average of the three AM and three PM scores preceding treatment.</description>
        <time_frame>Baseline and days 1 through 15 (average of 15 days of treatment)</time_frame>
        <population>Includes randomized participants with ≥1 valid post-Baseline visit, no major protocol violations, and evaluable data for the days 1-15 average.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Symptom Score (Assessed by Participant)</title>
          <description>Mean change from baseline (CFB), averaged over study days 1-15, is calculated for total symptom scores assessed by participants. Participants scored 8 symptoms (rhinorrhea; nasal stuffiness; nasal itching; sneezing; itching/burning eyes; tearing/watering eyes; eye redness; and ear/palate itching) in diaries on a scale from 0 (none) to 3 (severe). Scores sum to a total symptom score (range: 0-24); higher values indicate greater severity. A decrease in symptom severity is reflected by a negative CFB.
CFB is the 15-day average score minus baseline score. Scores were recorded twice daily, in morning (AM) and night (PM). Average AM/PM scores are first calculated separately, then averaged together to compute the 15-day average score. If diary entries were missing, an average AM or PM score was not calculated. If neither average AM nor PM score was calculated, total 15-day average score was not calculated. Baseline score is an average of the three AM and three PM scores preceding treatment.</description>
          <population>Includes randomized participants with ≥1 valid post-Baseline visit, no major protocol violations, and evaluable data for the days 1-15 average.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="4.1"/>
                    <measurement group_id="O2" value="14.2" spread="4.4"/>
                    <measurement group_id="O3" value="14.4" spread="4.5"/>
                    <measurement group_id="O4" value="14.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline Days 1-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="4.8"/>
                    <measurement group_id="O2" value="-4.8" spread="4.7"/>
                    <measurement group_id="O3" value="-3.8" spread="4.2"/>
                    <measurement group_id="O4" value="-2.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Nasal Symptom Score on Day 15 (Assessed by Physician)</title>
        <description>The mean change from baseline on study day 15 was calculated for total nasal symptom scores assessed by physician. Total nasal symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, and sneezing scores. Physician scored each symptom during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-12 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
        <time_frame>Baseline and study day 15</time_frame>
        <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Nasal Symptom Score on Day 15 (Assessed by Physician)</title>
          <description>The mean change from baseline on study day 15 was calculated for total nasal symptom scores assessed by physician. Total nasal symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, and sneezing scores. Physician scored each symptom during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-12 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
          <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="1.8"/>
                    <measurement group_id="O2" value="8.6" spread="1.8"/>
                    <measurement group_id="O3" value="8.6" spread="1.7"/>
                    <measurement group_id="O4" value="8.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="167"/>
                    <count group_id="O4" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="3.1"/>
                    <measurement group_id="O2" value="-4.2" spread="2.8"/>
                    <measurement group_id="O3" value="-3.1" spread="2.8"/>
                    <measurement group_id="O4" value="-2.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Symptom Score on Day 15 (Assessed by Physician)</title>
        <description>The mean change from baseline on study day 15 was calculated for total symptom scores assessed by physician. Total symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, sneezing, itching/burning eyes, tearing/watering eyes, redness of the eyes, and itching of the ears or palate scores. Physician scored each symptom during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-24 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
        <time_frame>Baseline and study day 15</time_frame>
        <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Symptom Score on Day 15 (Assessed by Physician)</title>
          <description>The mean change from baseline on study day 15 was calculated for total symptom scores assessed by physician. Total symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, sneezing, itching/burning eyes, tearing/watering eyes, redness of the eyes, and itching of the ears or palate scores. Physician scored each symptom during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-24 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
          <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="3.1"/>
                    <measurement group_id="O2" value="16.1" spread="3.4"/>
                    <measurement group_id="O3" value="15.9" spread="3.2"/>
                    <measurement group_id="O4" value="16.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="167"/>
                    <count group_id="O4" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="5.3"/>
                    <measurement group_id="O2" value="-8.0" spread="5.1"/>
                    <measurement group_id="O3" value="-6.2" spread="5.1"/>
                    <measurement group_id="O4" value="-5.4" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Nasal Symptom Score on Day 8 (Assessed by Physician)</title>
        <description>The mean change from baseline on study day 15 was calculated for total nasal symptom scores assessed by physician. Total nasal symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, and sneezing scores. Physician scored each symptom during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-12 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
        <time_frame>Baseline and study day 8</time_frame>
        <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Nasal Symptom Score on Day 8 (Assessed by Physician)</title>
          <description>The mean change from baseline on study day 15 was calculated for total nasal symptom scores assessed by physician. Total nasal symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, and sneezing scores. Physician scored each symptom during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-12 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
          <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="1.8"/>
                    <measurement group_id="O2" value="8.6" spread="1.8"/>
                    <measurement group_id="O3" value="8.6" spread="1.7"/>
                    <measurement group_id="O4" value="8.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="3.1"/>
                    <measurement group_id="O2" value="-3.6" spread="2.7"/>
                    <measurement group_id="O3" value="-2.6" spread="2.6"/>
                    <measurement group_id="O4" value="-2.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Symptom Score on Day 8 (Assessed by Physician)</title>
        <description>The mean change from baseline on study day 8 was calculated for total symptom scores assessed by physician. Total symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, sneezing, itching/burning eyes, tearing/watering eyes, redness of the eyes, and itching of the ears or palate scores. Physician scored each symptom during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-24 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
        <time_frame>Baseline and study day 8</time_frame>
        <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Symptom Score on Day 8 (Assessed by Physician)</title>
          <description>The mean change from baseline on study day 8 was calculated for total symptom scores assessed by physician. Total symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, sneezing, itching/burning eyes, tearing/watering eyes, redness of the eyes, and itching of the ears or palate scores. Physician scored each symptom during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-24 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
          <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="3.1"/>
                    <measurement group_id="O2" value="16.1" spread="3.4"/>
                    <measurement group_id="O3" value="15.9" spread="3.2"/>
                    <measurement group_id="O4" value="16.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="5.4"/>
                    <measurement group_id="O2" value="-6.9" spread="4.9"/>
                    <measurement group_id="O3" value="-5.2" spread="4.6"/>
                    <measurement group_id="O4" value="-4.6" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis (SAR) on Day 15 (Assessed by Physician)</title>
        <description>The mean change from baseline on study day 15 was calculated for overall condition of rhinitis. Physicians scored participant rhinitis condition during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe). A higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
        <time_frame>Baseline and study day 15</time_frame>
        <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis (SAR) on Day 15 (Assessed by Physician)</title>
          <description>The mean change from baseline on study day 15 was calculated for overall condition of rhinitis. Physicians scored participant rhinitis condition during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe). A higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
          <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.5"/>
                    <measurement group_id="O2" value="2.3" spread="0.5"/>
                    <measurement group_id="O3" value="2.3" spread="0.5"/>
                    <measurement group_id="O4" value="2.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="167"/>
                    <count group_id="O4" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.7"/>
                    <measurement group_id="O2" value="-0.9" spread="0.7"/>
                    <measurement group_id="O3" value="-0.6" spread="0.8"/>
                    <measurement group_id="O4" value="-0.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis (SAR) on Day 8 (Assessed by Physician)</title>
        <description>The mean change from baseline on study day 8 was calculated for overall condition of rhinitis. Physicians scored participant rhinitis condition during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe). A higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
        <time_frame>Baseline and study day 8</time_frame>
        <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis (SAR) on Day 8 (Assessed by Physician)</title>
          <description>The mean change from baseline on study day 8 was calculated for overall condition of rhinitis. Physicians scored participant rhinitis condition during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe). A higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.</description>
          <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.5"/>
                    <measurement group_id="O2" value="2.3" spread="0.5"/>
                    <measurement group_id="O3" value="2.3" spread="0.5"/>
                    <measurement group_id="O4" value="2.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change From Baseline Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.8"/>
                    <measurement group_id="O2" value="-0.7" spread="0.7"/>
                    <measurement group_id="O3" value="-0.5" spread="0.7"/>
                    <measurement group_id="O4" value="-0.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This analysis compares Change From Baseline values.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Therapy on Day 15 (Assessed by Physician)</title>
        <description>Mean response to therapy based on the participant's status relative to baseline. Physician scored participant's response on a scale from 1 (complete relief) to 5 (treatment failure) during study visit on study day 15. A higher value indicates weaker response.</description>
        <time_frame>Study day 15</time_frame>
        <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Therapy on Day 15 (Assessed by Physician)</title>
          <description>Mean response to therapy based on the participant's status relative to baseline. Physician scored participant's response on a scale from 1 (complete relief) to 5 (treatment failure) during study visit on study day 15. A higher value indicates weaker response.</description>
          <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.0"/>
                    <measurement group_id="O2" value="3.0" spread="1.0"/>
                    <measurement group_id="O3" value="3.4" spread="1.1"/>
                    <measurement group_id="O4" value="3.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Therapy on Day 8 (Assessed by Physician)</title>
        <description>Mean response to therapy based on the participant's status relative to baseline. Physician scored participant's response on a scale from 1 (complete relief) to 5 (treatment failure) during study visit on study day 8. A higher value indicates weaker response.</description>
        <time_frame>Study day 8</time_frame>
        <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 200 μg + Loratadine 10 mg</title>
            <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
          </group>
          <group group_id="O2">
            <title>MFNS 200 μg</title>
            <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
          </group>
          <group group_id="O3">
            <title>Loratadine 10 mg</title>
            <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Therapy on Day 8 (Assessed by Physician)</title>
          <description>Mean response to therapy based on the participant's status relative to baseline. Physician scored participant's response on a scale from 1 (complete relief) to 5 (treatment failure) during study visit on study day 8. A higher value indicates weaker response.</description>
          <population>All randomized participants with: ≥1 valid post-Baseline visit; no major protocol violations; and who had an observation for the respective endpoint prior to either significant dose noncompliance, or onset of an adverse event that may have interfered with allergic rhinitis assessment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.1"/>
                    <measurement group_id="O2" value="3.1" spread="1.0"/>
                    <measurement group_id="O3" value="3.4" spread="0.9"/>
                    <measurement group_id="O4" value="3.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 45 days.</time_frame>
      <desc>Analysis population includes all randomized participants with at least one post-Baseline evaluation. Adverse event (AE) preferred terms were converted from WHO-ART dictionary to the MedDRA version 12.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>MFNS Pus Loratadine</title>
          <description>Daily administration of 200 μg of MFNS plus oral dose of 10 mg loratadine tablet.</description>
        </group>
        <group group_id="E2">
          <title>MFNS 200</title>
          <description>Daily administration of 200 μg of MFNS plus oral placebo tablet.</description>
        </group>
        <group group_id="E3">
          <title>Loratadine</title>
          <description>Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Daily administration of placebo nasal spray plus oral placebo tablet.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="176"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="35" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="176"/>
                <counts group_id="E3" events="41" subjects_affected="33" subjects_at_risk="181"/>
                <counts group_id="E4" events="31" subjects_affected="21" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator agrees not to publish or publicly present any interim results of the Protocol study without the prior written consent of Sponsor. The Principal Investigator further agrees to provide thirty (30) days prior to submission for publication or presentation to Sponsor to review copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the Protocol study.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>AE Preferred Terms were converted from WHO-ART dictionary to the MedDRA version 12.0.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

